The importance of humoral immune responses in chronic rejection

Transplantation Reviews

Volumn 12, Issue 4, 1998, Pages 166-176

  Cramer, Donald V ^a   Shirwan, Haval ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001473341     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(98)80007-4     Document Type: Article

References (84)

1. Porter KA, Thomson WB, Owen K, et al. Obliterative vascular changes in four human kidney homotransplants. BMJ 1963, 2.639
2. Hume DM, Merrill JP, Miller BF, et al: Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955, 34:327
3. Porter KA, Calne RY, Zukoski CF: Vascular and other changes in 200 canine renal homografts treated with immunosuppressive drugs. Lab Invest 1964, 13.809
4. Cook DJ, Terasaki P. Long-term survival of kidney allografts in clinical transplants. UCLA Tissue Typing Manual 1987, p 227
5. McGiffin DC, Savunen T, Kirklin JK, et al: Cardiac transplant coronary artery disease: a multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg 1995, 109:1081
6. Cramer DV: Graft arteriosclerosis in heart transplantation, in Xanthus Intelligence Unit Report No. 13. Austin, TX, R.G. Landes, 1993
7. Gao S, Alderman EL, Schroeder JS, et al. Progressive coronary luminal narrowing after cardiac transplantation. Circulation 1990, 82:269
8. Pascoe EA, Barnhart GR, Carter WHJ, et al: The prevalence of cardiac allograft arteriosclerosis. Transplantation 1987, 44:838
9. Uretsky BF, Murali S, Reddy PS, et al: Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987, 76:827
10. Narrod J, Kormos R, Armitage JM, et al. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 1989, 5:418
11. Olivari MT, Homans DC, Wilson RF, et al: Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation 1989, 5:111
12. Rose EA, Pepino P, Barr ML, et al: Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992, 11:S120
13. Suciu-Foca N, Reed E, Marboe C, et al: The role of anti-HLA antibodies in heart transplantation. Transplantation 1991, 51:716
14. Hess ML, Hastillo A, Mohanakumar T, et al: Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983, 68: II94
15. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992, 11:s124
16. Tilney NL, Whitley WD, Diamond JR, et al: Chronic rejection: an undefined conundrum. Transplantation 1991, 52:389
17. Cramer DV, Chapman FA, Wu GD, et al: Cardiac transplantation in the rat. II: Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response. Transplantation 1990, 50.554
18. Kolb F, Heudes D, Mandet C, et al: Presensitization accelerates allograft arteriosclerosis. Transplantation 1996, 62:1401
19. Cramer DV, Qian S, Harnaha JB, et al: Cardiac transplantation in the rat. I: The effect of histocompatibility differences on graft arteriosclerosis. Transplantation 1989, 47:414
20. Cramer DV, Wu GD, Chapman FA, et al: Lymphoqte subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant 1992, 11:458
21. Adams DH, Tilney NL, Collins JJ, et al: Experimental graft arteriosclerosis. Transplantation 1992, 53:1115
22. Brunner-La Rocca HP, Schneider J, Kunzli A, et al: Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 1998, 65:538
23. Rose EA, Smith CR, Petrossian GA, et al: Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft arteriosclerosis. Surgery 1989, 106:203
24. Cramer DV: Cardiac transplantation: immune mechanisms and alloantigens involved in graft rejection. Crit Rev Immunol 1987, 7:1
25. Colvin RB: Cellular and molecular mechanisms of allograft rejection. Annu Rev Med 1990, 41:361
26. Carpenter CB, d'Apice AJF, Abbas AK: The role of antibodies in the rejection and enhancement of organ allografts. Adv Immunol 1976, 22:1
27. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al: Hyperacute reaction of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 1966, 1:662
28. Hammond EH, Yowell RL, Price GD, et al: Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 1992, 11:s111
29. Hammond EH, Yowell RI, Nunoda S, et al: Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Lung Transplant 1989, 8:430
30. Schmid C, Heemann U, Tilney NL: Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation 1997, 64:222
31. Russell ME, Wallace AT, Hancock WW, et al: Upregulation of cytokines associated with macrophage activation in the LEWIS-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation 1995, 59.572
32. Raisanen-Sokolowski A, Glysing-Jensen T, Koglin J, et al: Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-knockout recipients. Am J Pathol 1998, 152:359
33. Chitilian HV, Auchincloss H, Jr: The indirect pathway in graft rejection Curr Opin Organ Transplant 1997, 2:3
34. Liu Z, Sun Y, Xi Y, et al: Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993, 177:1643
35. Wilson DB, Blyth JL, Nowell PC: Quantitative studies on the mixed lymphocyte interaction in rats. J Exp Med 1968, 128:1157
36. Lechler RI, BatchelorJR: Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982, 155:31
37. Benham AM, Sawyer GJ, Fabre JW: Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation 1995, 59.1028
38. Steptoe RJ, Fu F, Li W, et al. Augmentation of dendritic cells in murine organ donors by flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol 1998, 159 5483
39. Shirwan II, Barwari L, Cramer DV: Alloantigen recognition is mediated by T cell receptors expressing restricted Vβ gene and diverse CDR3 loop and Jβ gene repertoires. Immunology 1997, 90:572
40. Braun MY, McCormack A, Webb G, et al: Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation 1993, 55:177
41. Benichou G, Takizawa PA, Olson CA, et al: Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992, 175:305
42. + T cell-dependent antibody-mediated graft rejection. Immunol Today 1992, 13.434
43. Lombardi G, Sidhu S, Batchelor R, et al: Anergic T cells as suppressor cells in vitro. Science 1994, p 1587
44. Klaus SJ, Pinchuk LM, Ochs HD, et al: Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol 1994, 152:5643
45. Foy TM, Aruffo A, Bajorath J, et al: Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996, 14:591
46. Jordan SC, Yap HK, Sakai RS, et al: Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation 1988, 46:585
47. Crisp SJ, Dunn MJ, Rose ML, et al: Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant 1994, 13:81
48. Kitamura D, Roes J, Kuhn R, et al: A B cell-deficient mouse by targeted disruption of the immunoglobulin μ chain gene. Nature 1991, 350:423
49. Russell PS, Chase CM, Colvin RB: Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997, 64:1531
50. Shi C, Lee WS, He Q, et al: Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996, 9.4051
51. Chow LH, Huh S, Jiang J, et al: Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 1996, 94:3079
52. Azuma H, Chandraker A, Nadeau KC, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996, 93:12439
53. Sun H, Subbotin V, Chen C, et al: Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTL4-IG and anti-CD40 ligand monoclonal antibody. Transplantation 1997, 64:1856
54. Harris PE, Bian H, Reed EF: Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997, 159:5697
55. Russell PS, Chase CM, Winn HJ, et al: Coronary atherosclerosis in transplanted mouse hearts. II: Importance of humoral immunity. J Immunol 1994, 152:5135
56. O'Connell TX, Mowbray JF: Arterial intimal thickening produced by alloantibody and xenoantibody. Transplantation 1973, 15:262
57. O'Connell TX, Mowbray JF: Effects of humoral transplantation antibody on the arterial intima of rabbits. Surgery 1973, 74:145
58. Klempnauer J, Steiniger B, Luck R, Gunther E. Genetic control of rat heart allograft rejection: effect of different MHC and non-MHC incompatibilities. Immunogenetics 1989, 30.81
59. b by allreactive cytotoxic T lymphocytes. Nature 1989, 341:749
60. Sherman LA, Chattopadhyay S: The molecular basis of allorecognition. Annu Rev Immunol 1993, 11:385
61. Fangmann J, Dalchau R, Fabre JW: Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992, 175: 1521
62. Sayegh MH, Khoury SJ, Hancock WW, et al: Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex antigens in the rat. Proc Natl Acad Sci USA 1992, 89:7762
63. + T-cell and B-cell responses after cardiac allograft rejection. Transplantation 1995, 59.401
64. Ciubotariu R, Liu Z, Colovai AI, et al: Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998, 101:398
65. Shirwan H, Wu GD, Barwari L, et al: Induction of allograft nonresponsiveness following intrathymic inoculation with donor class I allopeptides. 2. Evidence for persistent chronic rejection despite high levels of donor chimerism. Transplantation 1997, 64:1671
66. Vella JP, Spadafora-Ferreira M, Murphy B, et al: Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997, 64:795
67. Sawyer GJ, Dalchau R, Fabre JW: Indirect T-cell allorecognition: a cyclosporin A resistant pathway for T-cell help for antibody production to donor MHC antigens. Transpl Immunol 1993, 1:77
68. Wasowska B, Wieder KJ, Hancock WW, et al: Cytokine and alloantibody networks in long-term cardiac allografts in rat recipients treated with rapamycin. J Immunol 1996, 156:395
69. Vella JP, Vos L, Carpenter CB, et al. Role of indirect allorecognition in experimental late acute rejection. Transplantation 1997, 64:1823
70. Yin D, Fathman CG: CD4-positive suppressor cells block allotransplant rejection. J Immunol 1995, 154.6339
71. Mhoyan A, Baquerizo A, Cramer DV, et al: Intrathymic transplantation tolerance with class I major histocompatibility complex allopeptides: mechanisms of action. Circulation 1997, 94:I-54
72. Mhoyan A, Cramer DV, Baquerizo A, et al: Induction of allograft nonresponsiveness following intrathymic inoculation with donor class I allopeptides. 1: Correlation of graft survival with anti-donor IgG antibody subclasses. Transplantation 1997, 64:1665
73. Shirwan H, Mhoyan A, Leamer M, et al. The role of donor class I major histocompatibility complex peptides in the induction of allograft tolerance. Transplant Proc 1997, 29: 1134
74. Shirwan H, Mhoyan A, Oakley OH, et al: Presentation of donor class I MHC allopeptides to recipient T cells in the thymus induces immune nonresponsiveness to cardiac allografts in rats. Transplantation 1998, (in press)
75. Moore KW, O'Garra A, de Waal Malefyt R, et al: Interleukin 10. Annu Rev Immunol 1993, 11:165
76. Salazar-Onfray F, Charo J, Petersson M, et al: Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expression IL-10. J Immunol 1997, 159:3195
77. Qin Z, Noffz G, Mohaupt M, et al: Interleukin 10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997, 159:770
78. Steinbrink K, Wolfl M, Jonuleit H, et al: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159:4772
79. Osorio RW, Ascher NL, Stock PG: Prolongation of in VIVO mouse islet allograft survival by modulation of MHC class I antigen. Transplantation 1994, 57:783
80. Willems F, Marchant A, Delville JP, et al: Interleukin 10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994, 24:1007
81. -) B cells produce interleukin (IL)-10. Cell Immunol 1997, 175:164
82. Gill RG, Rosenberg AS, Lafferty KJ, et al: Characterization of primary T-cell subsets mediating rejection of pancreatic islet grafts. J Immunol 1989, 143:2176
83. Hancock WW, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993, 56:643
84. + suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996, 9:331